The latest price target for Marker Therapeutics (NASDAQ:MRKR) was reported by Ladenburg Thalmann on October 21, 2024. The analyst firm set a price target for $19.00 expecting MRKR to rise to within 12 months (a possible 1065.64% upside). 2 analyst firms have reported ratings in the last year.

The latest analyst rating for Marker Therapeutics (NASDAQ:MRKR) was provided by Ladenburg Thalmann, and Marker Therapeutics maintained their buy rating.

There is no last upgrade for Marker Therapeutics

There is no last downgrade for Marker Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Marker Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Marker Therapeutics was filed on October 21, 2024 so you should expect the next rating to be made available sometime around October 21, 2025.

While ratings are subjective and will change, the latest Marker Therapeutics (MRKR) rating was a maintained with a price target of $11.00 to $19.00. The current price Marker Therapeutics (MRKR) is trading at is $1.63, which is out of the analyst’s predicted range.